Watch past educational presentations and see live events in real time
Reference our medication guides for helpful information
Apply for the 2019 ACR/ARP Annual Meeting FIT Scholarship. The deadline is July 31.
Make a choice that matters
The best care starts with the best information
Encourage your rheumatology fellows-in-training to apply for the 2019 ACR/ARP Annual Meeting FIT Scholarship. The deadline to apply is July 31.
Denosumab (Prolia) is a biologic medication used to prevent fragile bones, also known as osteoporosis, and bone fractures. As a biologic drug, it is man-made and closely resembles proteins, called antibodies, which naturally occur in the body. In this case, it stops a molecule, called RANKL, which normally causes bone turnover. By blocking RANKL, it helps to strengthen bones. Denosumab is generally not viewed as a first line therapy and is usually given to patients when they are unable to take bisphosphonates or have unsuccessful results.
Denosumab is given as an injection just under the skin. It is given by your doctor or nurse. The usual dose is 60mg every six months, and it should be taken with calcium (1000mg daily) and vitamin D (at least 400 IU) supplementation. Denosumab works quickly - within three days of an injection, the effects on reducing bone turnover can be detected in the blood; the drug also stays in the blood for several months after stopping the medicine. Denosumab may be given in combination with other agents to reduce bone turnover.
The most common side effects that patients experience are back pain, pain in the hands and feet, and increased cholesterol. The pain from denosumab can last a few days up to a few months after administration.</p>
The rarer, but worrisome side effects include an increased risk for infections (especially if you’re already taking medications that lower your immune system), low calcium levels (called hypocalcemia), breakdown of bones in the jaw (called osteonecrosis of the jaw), and severe allergic reactions including anaphylaxis.
Some symptoms may occur normally while taking denosumab, however, you should notify your doctor if you have these symptoms while taking this medication: tingling of the hands or around the mouth, new pain in the jaw, or fevers or other signs of infection.
Make sure to notify your other physicians while you are taking this drug. If you are pregnant or considering pregnancy, let your doctor know before starting this medication. Women should discuss birth control with their primary care physicians or gynecologists. Breast-feeding should be avoided while taking denosumab because the drug can enter breast milk.
Updated June 2018 by Luke Barre, MD and reviewed by the American College of Rheumatology Communications and Marketing Committee.
This information provided for general education only. Individuals should consult a qualified health care provider for professional medical advice, diagnosis and treatment of a medical or health condition.